Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinoma

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 60-68

  Sivachandran, Nirojini ^a   Dawson, Christopher W ^b   Young, Lawrence S ^b   Liu, Fei Fei ^c   Middeldorp, Jaap ^d   Frappier, Lori ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Amsterdam Gastroenterology Metabolism   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; EPSTEIN BARR VIRUS ANTIGEN 1; MUTANT PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; PROTEINASE; UBIQUITIN SPECIFIC PROTEASE 7; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL NUCLEUS INCLUSION BODY; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; PRIMARY TUMOR; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; STOMACH CARCINOMA; TUMOR BIOPSY;

CARCINOMA; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; INTRANUCLEAR INCLUSION BODIES; NUCLEAR PROTEINS; PROTEIN BINDING; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 84862958150     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05623-11     Document Type: Article

References (48)

1. Bernardi R, Pandolfi PP. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8:1006 -1016.
2. Catalano V, et al. 2009. Gastric cancer. Crit. Rev. Oncol. Hematol. 71: 127-164.
3. Cheng TC, et al. 2010. Expression of Epstein-Barr nuclear antigen 1 in gastric carcinoma cells is associated with enhanced tumorigenicity and reduced cisplatin sensitivity. Int. J. Oncol. 36:151-160.
4. de Stanchina E, et al. 2004. PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 13:523-535.
5. Everett R, et al. 1997. A novel ubiquitin-specific protease is dyamically associted with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 16:1519 -1530.
6. Everett RD, Chelbi-Alix MK. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830.
7. Fogal V, et al. 2000. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19:6185- 6195.
8. Frappier L. 2004. Viral plasmids in mammalian cells, p 325-339. InFunnell BE, Phillips GJ (ed), Plasmid biology. ASM Press, Washington, DC.
9. Fukayama M. 2010. Epstein-Barr virus and gastric carcinoma. Pathol. Int. 60:337-350.
10. Fukayama M, Hino R, Uozaki H. 2008. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci. 99: 1726-1733.
11. Gruhne B, et al. 2009. The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc. Natl. Acad. Sci. U. S. A. 106:2313-2318.
12. Guo A, et al. 2000. The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2:730 -736.
13. Gurrieri C, et al. 2004. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 96:269 -279.
14. Holowaty MN, Sheng Y, Nguyen T, Arrowsmith C, Frappier L. 2003. Protein interaction domains of the ubiqutin specific protease, USP7/ HAUSP. J. Biol. Chem. 278:47753- 47761.
15. Holowaty MN, et al. 2003. Protein profiling with Epstein-Barr nuclear antigen 1 reveals an interaction with the herpesvirus-associated ubiquitinspecific protease HAUSP/USP7. J. Biol. Chem. 278:29987-29994.
16. Ian MX, Lan SZ, Cheng ZF, Dan H, Qiong LH. 2008. Suppression of EBNA1 expression inhibits growth of EBV-positive NK/T cell lymphoma cells. Cancer Biol. Ther. 7:1602-1606.
17. Imai S, et al. 1994. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc. Natl. Acad. Sci. U. S. A. 91:9131-9135.
18. Kennedy G, Komano J, Sugden B. 2003. Epstein-Barr virus provide a survival factor to Burkitt's lymphomas. Proc. Natl. Acad. Sci. U. S. A. 100:14269 -14274.
19. Lu J, et al. 2011. Epstein-Barr virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through upregulation of survivin. Virology 410:64 -75.
20. Luo J, Solimini NL, Elledge SJ. 2009. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823- 837.
21. Miller WH, Jr, Schipper HM, Lee JS, Singer J, Waxman S. 2002. Mechanisms of action of arsenic trioxide. Cancer Res. 62:3893-3903.
22. Muller M, et al. 1998. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188: 2033-2045.
23. Oh ST, Cha JH, Shin DJ, Yoon SK, Lee SK. 2007. Establishment and characterization of an in vivo model for Epstein-Barr virus positive gastric carcinoma. J. Med. Virol. 79:1343-1348.
24. Pearson M, et al. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406:207-210.
25. Ryan JL, et al. 2009. High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma. Lab. Invest. 89:80 -90.
26. Saridakis V, et al. 2005. Structure of the p53 binding domain of HAUSP/ USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBVmediated immortalization. Mol. Cell 18:25-36.
27. Sarkari F, Wang X, Nguyen T, Frappier L. 2011. The herpesvirus associated ubiquitin specific protease, USP7, is a negative regulator of PML proteins and PML nuclear bodies. PLoS One 6:e16598.
28. Scaglioni PP, et al. 2006. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126:269 -283.
29. Scaglioni PP, et al. 2008. CK2 mediates phosphorylation and ubiquitinmediated degradation of the PML tumor suppressor. Mol. Cell. Biochem. 316:149 -154.
30. Shi W, et al. 2003. Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int. J. Cancer 104:195-203.
31. Shibata D, Weiss LM. 1992. Epstein-Barr virus-associated gastric adenocarcinoma. Am. J. Pathol. 140:769 -774.
32. Sivachandran N, Cao JY, Frappier L. 2010. Epstein-Barr virus nuclear antigen 1 hijacks the host kinase CK2 to disrupt PML nuclear bodies. J. Virol. 84:11113-11123.
33. Sivachandran N, Sarkari F, Frappier L. 2008. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through the disruption of PML nuclear bodies. PLoS Pathog. 4:e1000170.
34. Stewart S, et al. 2004. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc. Natl. Acad. Sci. U. S. A. 101:15730 -15735.
35. Takada K. 2000. Epstein-Barr virus and gastric carcinoma. Mol. Pathol. 53:255-261.
36. Takahashi Y, Lallemand-Breitenbach V, Zhu J, de The H. 2004. PML nuclear bodies and apoptosis. Oncogene 23:2819 -2824.
37. Trotman LC, et al. 2006. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441:523-527.
38. Uemura Y, et al. 1994. A unique morphology of Epstein-Barr virusrelated early gastric carcinoma. Cancer Epidemiol. Biomarkers Prev. 3:607- 611.
39. Valentine R, et al. 2010. Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation. Mol. Cancer 9:1.
40. van Beek J, et al. 2004. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J. Clin. Oncol. 22:664-670.
41. van Beek J, et al. 2002. A rapid and reliable enzyme immunoassay PCREBNA1 based screening method to identify EBV-carrying gastric carcinomas. Mod. Pathol. 15:870-877.
42. van Beek J, et al. 2006. Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am. J. Surg. Pathol. 30:59-65.
43. Wang ZG, et al. 1998. Role of PML in cell growth and the retinoic acid pathway. Science 279:1547-1551.
44. Wei J, et al. 2010. Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. Gastroenterology 139:1333-1343.
45. Wilson JB, Bell JL, Levine AJ. 1996. Expression of Epstein-Barr virus nuclar antigen-1 induces B cell neoplasia in transgenic mice. EMBO 15: 3117-3126.
46. Wu H, Kapoor P, Frappier L. 2002. Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1. J. Virol. 76:2480 -2490.
47. Yin Q, Flemington EK. 2006. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBVdependent tumor cells. Virology. 346:385-393.
48. Zhong S, et al. 1999. A role for PML and the nuclear body in genomic stability. Oncogene 18:7941-7947.